ImClone sales staff cut by half

Eli Lilly has already found ways to streamline ImClone Systems. Just a couple of months after agreeing to buy the Erbitux maker, Lilly has cut almost half of ImClone's sales staff. That amounts to about 30 of nearly 70 positions, and it "takes the overall size of the sales force back to a mid-2007 sales model," a spokeswoman told Pharmalot.

Of course, ImClone doesn't market Erbitux on its own; partner Bristol-Myers Squibb also has a cadre of Erbitux reps. And the spokeswoman hinted that Lilly reps might get in on the act: "[W]e will continue to ... create synergies across the Lilly and ImClone field sales organizations for the benefit of the prescribers and patients we serve."

- see the Pharmalot post

ALSO: ImClone Systems, Eli Lilly and Bristol-Myers Squibb have asked the FDA to broaden the use of their cancer drug Erbitux to include first-line treatment of non-small cell lung cancer. Release

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.